November 19, 2026 · The American journal of cardiology · DOI: 10.1016/j.amjcard.2026.11.023

Cardiovascular Outcomes of Semaglutide in Adults With Congenital Heart Disease.

Listen to this summary

This retrospective TriNetX cohort study asked whether semaglutide, compared with DPP-4 inhibitors, is associated with better outcomes in adults with congenital heart disease and type 2 diabetes, a population excluded from cardiovascular outcome trials. In 1,422 propensity-matched pairs followed for 3 years, semaglutide was associated with lower all-cause mortality (HR 0.66), hospitalization (HR 0.68), and ED visits (HR 0.85), along with lower MACE, heart failure, and stroke, though a prespecified negative control was elevated, suggesting residual confounding from differences in healthcare engagement. The authors conclude the findings are hypothesis-generating only, given the observational design and imbalances such as more aortic valve disease among semaglutide users.

Ino Chough, Ali Reza Rahmani, Andreas Kalogeropoulos

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play